- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | OSR Holdings, Inc.: CEO Statement to Shareholders | 194 | ACCESS Newswire | BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value CreationAs the compliance deadline under the minimum bid requirement of NASDAQ approaches... ► Artikel lesen | |
| 27.01. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.01. | OSR Holdings, Inc.: OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries | 498 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment... ► Artikel lesen | |
| 14.01. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Woori IO shareholders approve final step in OSR Holdings acquisition | 4 | Investing.com | ||
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | Woori IO-Aktionäre stimmen Übernahme durch OSR Holdings zu | 2 | Investing.com Deutsch | ||
| 19.12.25 | OSR Holdings Inc.: Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings | 361 | PR Newswire | Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university
... ► Artikel lesen | |
| 04.12.25 | Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement | 399 | Newsfile | New York, New York--(Newsfile Corp. - December 4, 2025) - Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (NASDAQ: OSRH), reaffirming its Buy-Emerging rating and 12-month... ► Artikel lesen | |
| 25.11.25 | OSR Holdings, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.11.25 | OSR Enterprises Acquires MAISENSE To Expand Next-Generation AI Compute Capabilities | 2 | pulse2.com | ||
| 25.11.25 | EQS-News: OSR Enterprises AG: Die Schweizer OSR Enterprises AG unter der Leitung von Orit Shifman gab heute die Übernahme von MAISENSE LTD bekannt, einem Hyperscale-Plasmonik-SoC-Unternehmen | 453 | EQS Group (DE) | EQS-News: OSR Enterprises AG
/ Schlagwort(e): Fusionen & Übernahmen
Die Schweizer OSR Enterprises AG unter der Leitung von Orit Shifman gab heute die Übernahme von MAISENSE LTD... ► Artikel lesen | |
| 21.11.25 | Potenzieller Lizenzdeal für Krebstherapie katapultiert OSR Holdings-Aktie nach oben | 5 | Investing.com Deutsch | ||
| 14.11.25 | OSR Holdings names Vaximm co-founder as CEO of subsidiary | 5 | Investing.com | ||
| 14.11.25 | OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion | 169 | PR Newswire | BELLEVUE, Wash., Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm... ► Artikel lesen | |
| 12.11.25 | OSR Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21.10.25 | "You'll get nothing": OSR CEO's message sparks employee revolt amid collapse | 9 | CTech | ||
| 20.10.25 | Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target | 356 | Newsfile | New York, New York--(Newsfile Corp. - October 20, 2025) - Emerging Growth Research today announced the initiation of coverage on OSR Holdings, Inc. (NASDAQ: OSRH) with a Buy-Emerging rating and a 12-month... ► Artikel lesen | |
| 16.10.25 | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10.25 | OSR Holdings announces definitive agreement to acquire Woori IO | 6 | Seeking Alpha | ||
| 14.10.25 | OSR Holdings übernimmt südkoreanischen Spezialisten für nicht-invasive Blutzuckermessung | 3 | Investing.com Deutsch |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,568 | +2,10 % | PacBio Completes Sale of Short-Read Sequencing Assets | MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,127 | -100,00 % | Carisma Therapeutics Inc.: Carisma Announces Delisting from Nasdaq and SEC Deregistration | PHILADELPHIA, Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 4,826 | +0,88 % | SD-Tipp CytomX: Was tun nach +1.438% in 10 Monaten? | Unsere Aktien-Empfehlung CytomX Therapeutics erlebt derzeit einen außergewöhnlich starken Kursverlauf. Innerhalb kurzer Zeit hat sich das Papier von einem lange übersehenen Small-Cap-Titel zu einem... ► Artikel lesen | |
| CAPRICOR | 19,000 | -9,31 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| CORMEDIX | 6,500 | 0,00 % | CorMedix kündigt Aktienrückkaufprogramm über 75 Mio. $ an - Aktie legt zu | ||
| MINERVA NEUROSCIENCES | 3,620 | -10,84 % | Minerva Neurosciences, Inc. - 8-K, Current Report | ||
| REPLIMUNE | 6,450 | -1,53 % | Replimune, Inc.: Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update | WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,142 | -0,70 % | Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors | Regulatory News:
Valerio Therapeutics ("Valerio Therapeutics" or the "Company") (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,220 | +10,91 % | Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer | SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery... ► Artikel lesen | |
| IO BIOTECH | 0,350 | +9,27 % | IO Biotech Provides Corporate Update | Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 15,260 | +7,46 % | Alto Neuroscience, Inc.: Alto Neuroscience to Participate in Upcoming Investor Conferences | Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that... ► Artikel lesen | |
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics Holdings, Inc.: CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Umsatz und Ergebnis des vierten Quartals hätten die Erwartungen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report |
OSR HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,550 Euro und damit +6,94 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.